Mode
Text Size
Log in / Sign up
Phase 2 N=200 Randomized Quadruple-blind Treatment

Varenicline for Alcohol Dependence

Alcoholism

Enrolled (actual)
200
Serious AEs
2.0%
Results posted
Aug 2014
Primary outcome: Primary: Weekly Percentage of Heavy Drinking Days — 37.9; 48.4 percentage of heavy drinking days

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Varenicline (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Primary completion
Jun 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Weekly Percentage of Heavy Drinking Days
37.9; 48.4

Summary

The primary objective of this study is to assess the efficacy of varenicline in reducing the proportion of heavy drinking days during the last 8 weeks of treatment in subjects with alcohol dependence confirmed by Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR) criteria and who frequently consume 10 or more drinks per drinking day for men and 8 or more drinks for women (designated as "very heavy" drinkers).

Eligibility Criteria

Inclusion Criteria

  • Be at least 18 years of age.
  • Have a current (past 12 months) DSM-IV-TR diagnosis of alcohol dependence.
  • Be seeking treatment for alcohol dependence and desire a reduction or cessation of drinking.
  • Be able to verbalize an understanding of the consent form, able to provide written informed consent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English and able to complete the questionnaires required by the protocol.
  • Agree (if the subject is female and of child bearing potential) to use at least one of the following methods of birth control, unless she is surgically sterile, partner is surgically sterile or she is postmenopausal:
  • oral contraceptives,
  • contraceptive sponge,
  • patch,
  • double barrier (diaphragm/spermicidal or condom/spermicidal),
  • intrauterine contraceptive system,
  • levonorgestrel implant,
  • medroxyprogesterone acetate contraceptive injection,
  • complete abstinence from sexual intercourse,
  • hormonal vaginal contraceptive ring, and/or
  • Be able to take oral medication and be willing to adhere to the medication regimen
  • Complete all assessments required at screening and baseline.
  • Provide evidence of stable residence in the last 2 months prior to randomization, have reasonable transportation arrangements to the study site, and have no plans to move within the next 3 months or unresolved legal problems. Subjects must provide contact information of someone, such as a family member, spouse, or significant other, who may be able to contact the subject in case of a missed clinic appointment.
  • Be willing to discontinue the use of nicotine replacement therapies prior to randomization and refrain from using nicotine replacement therapies during the course of the study.
  • Have a blood alcohol content (BAC) by breathalyzer equal to 0.000 when s/he signed the informed consent document.
  • Be someone who in the opinion of the investigator would be expected to complete the study protocol.
  • Agree to the schedule of visits, verbally acknowledge that s/he will be able to attend each scheduled visit, participate in phone visits and that s/he does not have any already scheduled events or a job that may interfere with study participation.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01146613). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search